Discussions with leaders: Czernin speaks with Patricia A. Ganz, an internationally recognized medical oncologist, about her pioneering work in quality-of-life outcomes and cancer survivorship.
Page 1506
AI deployment and governance ethics: Herington and members of the SNMMI Artificial Intelligence Task Force identify 4 major ethical risks in deployment of AI medical devices and offer preliminary recommendations for managing these risks.
Page 1509
Looking ahead to actinium: Zimmermann summarizes 5 different technologies for production of 225Ac and reviews remaining issues to be resolved before widespread clinical application of 225Ac-labeled agents.
Page 1516
TSPO PET in glioblastoma: Albert and colleagues investigate the association of 18-kDa translocator protein PET imaging results with survival outcomes in a cohort of patients with histologically proven isocitrate dehydrogenase–wild-type glioblastoma.
Page 1519
PSMA imaging and expression in GBM: van Lith and colleagues quantify uptake of various PSMA-targeting tracers in glioblastoma multiforme and correlate the results with PSMA expression in tumor biopsy samples from the same patients.
Page 1526
68Ga-FAPI PET and uHCC response: Wu and colleagues compare baseline 68Ga-labeled fibroblast activation protein inhibitor PET/CT and 18F-FDG PET/CT in response and survival prediction in unresectable hepatocellular carcinoma treated with the programmed cell death 1 inhibitor and lenvatinib.
Page 1532
68Ga-SSO-120 PET in SCLC: Kersting and colleagues report on tumor uptake and detection rates of PET using the 68Ga-labeled somatostatin receptor 2 antagonist satoreotide trizoxetan in comparison to 18F-FDG PET in initial staging of small cell lung cancer.
Page 1540
[68Ga]PSMA PET and bPFS prediction: Chen and colleagues explore the association between changes on [68Ga]PSMA PET/CT and biochemical progression-free survival in high-risk patients who underwent neoadjuvant therapy before radical prostatectomy.
Page 1550
68Ga-PSMA PET during 223Ra therapy: de Jong and colleagues determine the utility of 68Ga-PSMA PET/CT for response evaluation of 223Ra treatment in patients with metastatic castration-resistant prostate cancer.
Page 1556
SN procedure in MiN0 PSMA PET: Duin and colleagues assess the diagnostic value of the sentinel node procedure for lymph node staging in primary intermediate- and high-risk prostate cancer patients with node-negative results on PSMA PET/CT.
Page 1563
[177Lu]Lu-PSMA-617 patient waste: Graves evaluates the relative radiation safety merits of contaminated waste disposal in the normal household stream in comparison to other management strategies in patients with metastatic castration-resistant prostate cancer undergoing radiopharmaceutical treatment.
Page 1567
Radioligand therapy in CKD: Mercolli and colleagues describe dosimetric evaluation of PSMA-based radioligand treatment for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease.
Page 1570
[225Ac]Ac-PSMA in end-stage mCRPC: Alan-Selcuk and colleagues retrospectively analyze the outcomes of 23 patients with advanced-stage metastatic castration-resistant prostate cancer refractory to [177Lu]Lu-PSMA and treated with [225Ac]Ac-PSMA.
Page 1574
mHTT PET in an NHP model of HD: Bertoglio and colleagues validate the novel radioligand 11C-CHDI-180R using PET imaging for quantification of cerebral mutant huntingtin protein aggregates in a macaque model of Huntington disease.
Page 1581
Biogen OGA PET: Cook and colleagues detail development of 2 11C-labeled PET tracers targeting O-GlcNAcase, a protein with a potential role in tau aggregation in Alzheimer disease, through studies in rodents, human brain tissue, and nonhuman primates.
Page 1588
Automated 18F-FET PET response assessment: Gutsche and colleagues report on a method for automated metabolic tumor volume segmentation in amino acid PET imaging and evaluate its performance for response assessment in patients with gliomas.
Page 1594
Machine learning in DLBCL prognostication: Zhao and colleagues outline an analytic approach based on [18F]FDG PET radiomics using stacking ensemble learning to improve outcome prediction in diffuse large B-cell lymphoma.
Page 1603
Single-time-point dosimetry after PRRT: Chicheportiche and colleagues describe and validate a multiple-linear-regression model to predict absorbed doses in 177Lu-DOTATATE peptide receptor radionuclide therapy from a single-time-point posttreatment study.
Page 1610
Single- vs. multiple-time-point dosimetry: Scheuermann and Pryma offer perspective on the importance of dosimetry in radiopharmaceutical therapy and question the advantages of simplified approaches in a complex field with many unresolved questions.
Page 1617
177Lu or 161Tb TRT: Larouze and colleagues compare uniform and nonuniform targeted radionuclide therapy with these agents within tumor cell clusters using the Monte Carlo code CELLDOSE and suggest that dual targeting may minimize heterogeneity in results.
Page 1619
161Tb-based radioligand therapy: Tschan and colleagues assess the dosimetry and therapeutic efficacy of 161Tb and 177Lu in tumor-bearing mice using SibuDAB and PSMA-I&T, which differ in blood residence time and tumor uptake.
Page 1625
TCP and Monte Carlo dosimetry model: Mellhammar and colleagues calculate tumor control probability from dosimetry simulations of heterogeneous absorbed dose distributions within xenografts treated with PSMA-617–ligated radioactivity.
Page 1632
Immuno-PET and ADC efficacy: Brown and colleagues use the 89Zr- or 64Cu-labeled anti-HER2 antibody trastuzumab to investigate different dosing regimens of antibody–drug conjugate therapy with and without coadministration of lovastatin in 2 xenografted models.
Page 1638
Ambient light–resistant SWIRFI: Mc Larney and colleagues explore in preclinical studies the potential of pH low-insertion peptide conjugated to indocyanine green, currently in clinical trials, as a candidate for cancer-targeted shortwave infrared fluorescence imaging.
Page 1647
64Cu- and 68Ga-labeled GRPR ligands: Koller and colleagues research theranostic applications of a novel gastrin-releasing peptide receptor ligand with improved metabolic stability and potential for enhancing diagnostic and therapeutic efficacy.
Page 1654
Postinfarction renal fibrosis and PET: Unterrainer and colleagues provide a case report on the use of [68Ga]Ga–fibroblast activation protein inhibitor–46 PET for visualization of postinfarction renal fibrosis.
Page 1660
- © 2023 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.